Genedrive Expands Application of CYP2C19-ID Kit to Acute Coronary Syndrome in New Clinical Trial

PUBLISHED: 13 May 2025 @ 18:03 | Comments (0) | More info about Fiona Craig

Genedrive plc (LSE:GDR) has announced a significant development in the clinical application of its Genedrive® CYP2C19-ID Kit, which will now be evaluated for use in Acute Coronary Syndrome (ACS) patients. This trial is being led by Manchester University Foundation Trust in collaboration with the GUIDE PCI programme and the British Heart Foundation.

The study aims to assess the impact and practicality of using rapid point-of-care genetic testing in cardiovascular care. Specifically, it will explore how the CYP2C19-ID Kit can improve treatment decisions and patient outcomes by enabling clinicians to tailor therapies based on individual genetic profiles. The initiative follows the American Heart Association’s recommendations for implementing genetic testing in cardiovascular treatment pathways and is designed to pave the way for broader clinical adoption.

If successful, the trial could lead to integration of the Genedrive® CYP2C19-ID Kit into routine practice at a wider scale, potentially enhancing outcomes and optimizing resource use in healthcare systems.

About Genedrive plc

Genedrive plc is a UK-based pharmacogenetics company focused on developing rapid, cost-effective genetic testing platforms for use at the point of care. These systems are built to assist healthcare professionals in making timely and personalized decisions about medications and dosages, particularly in emergency and acute settings. The company’s key offerings include the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit—both supported by the NHS and developed in close partnership with NHS institutions.

Average Daily Trading Volume: 4,580,297
Technical Outlook: Strong Sell
Current Market Capitalization: £9.28 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.